KM Research Hub
← 返回论文库
已完成 入排:待复核 图源:可得 入排置信度 0.70

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.

Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Fumihiko Urabe, Pawel Rajwa, Alberto Briganti, Shahrokh F Shariat, Nobuaki Matsubara, Takahiro Kimura, Akihiro Hirakawa

Cancer 131(7) e35819

PMID40106307
PMCIDPMC11922167
DOI10.1002/cncr.35819
发表日期2025-03-19
入排依据:The record describes a subgroup/heterogeneity analysis of a Phase III randomized trial (TITAN) comparing apalutamide vs. placebo. While it meets several criteria (oncology, human, randomized, Phase III, time-to-event endpoints), it is not the primary or definitive result report of the trial. The report type is 'subgroup', which is excluded per the rules.
摘要

摘要

BACKGROUND: Investigation remains incomplete regarding potential variations in the effect of androgen receptor pathway inhibitors, including apalutamide, based on baseline tumor burden in patients with metastatic castration-sensitive prostate cancer (mCSPC). METHODS: The authors analyzed individual participant-level data from 1052 patients with mCSPC who were randomized in the TITAN trial (apalutamide vs. placebo, both with androgen-deprivation therapy). Outcomes included radiographic progression-free survival (PFS), second PFS (PFS2), and overall survival (OS). Multivariable Cox proportional hazards regression models, with and without restricted cubic splines, were used to determine the association between apalutamide benefit and bone metastasis count or visceral metastasis. Subgroup treatment effects were quantified based on inverse probability of treatment weighting-adjusted hazard ratios (HRs). RESULTS: Analysis using restricted cubic splines indicated that apalutamide provided less benefit for PFS2 and OS in patients with fewer bone metastases. The authors also found evidence of a heterogeneous effect of apalutamide on PFS2 and OS between patients with two or less bone metastases and those with three or more bone metastases. In patients who had two or less bone metastases, there was no evidence of a benefit from apalutamide for radiographic PFS (HR, 0.65; 95% confidence interval [CI], 0.35-1.22), PFS2 (HR, 1.18; 95% CI, 0.66-2.12), or OS (HR, 1.05; 95% CI, 0.60-1.83). No evidence of an association was noted between visceral metastasis and apalutamide benefit. CONCLUSIONS: The addition of apalutamide to androgen-deprivation therapy may provide less benefit in patients with mCSPC who have fewer bone metastases. Counting baseline bone metastases may help identify optimal candidates for apalutamide treatment of mCSPC. CLINICAL TRIALS REGISTRATION: NCT02489318 PLAIN LANGUAGE SUMMARY: In an analysis of individual participant data from a trial (the TITAN trial) in patients with metastatic (spreading) castration-sensitive prostate cancer, treatment intensification based on the addition new drugs to standard androgen-deprivation therapy (ADT) was analyzed and compared with the effects in patients who received only standard ADT. Compared with ADT alone, the survival benefit of adding the new drug apalutamide to standard ADT varied according to the number of bone metastases, but no association was observed between the spread of cancer to soft tissues and organs and a survival benefit from adding apalutamide. The results indicate that counting the number of bone metastases may help identify which patients with metastatic castration-sensitive prostate cancer are optimal candidates for treatment intensification with the addition of apalutamide to standard ADT.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

FIGURE 2

FIGURE 2 Inverse probability of treatment weighting‐adjusted Kaplan–Meier plots based on bone metastasis count. (A–F) Inverse probability of treatment weighting‐adjusted Kaplan–Meier plots by treatment, with subgroups based on bone metastasis count (one or two vs. three or more). Solid lines represent point estimates, and shaded areas represent 95% CIs. HRs were estimated based on inverse probability of treatment weighting‐adjusted Cox proportional hazards regression models. HRs < 1.0 favor apalutamide. CI indicates confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting; OS, overall survival; PFS, progression‐free survival; PFS2, second progression‐free survival; rPFS, radiographic progression‐free survival.

A

rPFS

FIGURE 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS2

FIGURE 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
C

OS

FIGURE 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
D

rPFS

FIGURE 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

PFS2

FIGURE 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

OS

FIGURE 2 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Associations between effect of apalutamide and bone metastasis count. Splines with 95% CIs for HRs for (A) rPFS, (B) PFS2, and (C) OS. Solid lines represent point estimates, and shaded areas represent 95% CIs. HRs < 1.0 favor apalutamide, whereas HRs >1.0 indicate favorable outcomes with placebo. CI indicates confidence interval; HRs, hazard ratios; OS, overall survival; PFS, progression‐free survival; PFS2, second progression‐free survival; rPFS, radiographic progression‐free survival.
非 KM Figure
FIGURE 3FIGURE 3 Inverse probability of treatment weighting‐adjusted hazard ratios by bone metastasis count. (A–C) Forest plots showing HRs estimated from IPFW‐adjusted Cox proportional hazards regression model plus ADT based on bone metastasis count. Bone metastasis counts were categorized based on the quartiles: from the minimum to the first quartile (Q1; one or two bone metastases), from the first to the second quartile (Q2; from three to six bone metastases), from the second to the third quartile (Q3; (from seven to 20 bone metastases), and from the third quartile to the maximum (from 21 to 50 bone metastases). HRs < 1.0 indicates favorable outcomes for patients who received apalutamide plus ADT compared with those who received placebo plus ADT. ADT indicates androgen‐deprivation therapy; CI, confidence interval; HRs, hazard ratios; IPTW, inverse probability of treatment weighting; OS, overall survival; PFS, progression‐free survival; PFS2, second progression‐free survival; Q, quartile; rPFS, radiographic progression‐free survival.
非 KM Figure
FIGURE 4FIGURE 4 Difference in inverse probability of treatment weighting‐adjusted restricted mean survival time by bone metastasis count. (A–C) Forest plots showing differences in inverse probability of treatment weighting‐adjusted restricted mean survival times for rPFS and OS between patients who received apalutamide plus ADT and those who received placebo plus ADT based on bone metastasis count. Bone metastasis counts were categorized based on the quartiles: from the minimum to the first quartile (Q1; one or two bone metastases), from the first to the second quartile (Q2; from three to six bone metastases), from the second to the third quartile (Q3; from seven to 20 bone metastases), and from the third quartile to the maximum (from 21 to 50 bone metastases). Differences greater than zero indicate favorable outcomes for patients who received apalutamide plus ADT compared with those who received placebo plus ADT. The truncation times were set at the minimum of the longest observation times among the subgroups (25.9 months for rPFS, 46.9 months for PFS2, and 47.6 months for OS). ADT indicates androgen‐deprivation therapy; CI, confidence interval; HRs, hazard ratios; IPTW, inverse probability of treatment weighting; OS, overall survival; PFS, progression‐free survival; PFS2, second progression‐free survival; Q, quartile; RMST, restricted mean survival time; rPFS, radiographic progression‐free survival.
非 KM Figure